SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Triglycerides Revisited: is Hypertriglyceridaemia a Necessary Therapeutic Target in Cardiovascular Disease?

Drexel, H; Tamargo, J; Kaski, JC; Lewis, BS; Saely, CH; Fraunberger, P; Dobrev, D; Komiyama, M; Plattner, T; Agewall, S; et al. Drexel, H; Tamargo, J; Kaski, JC; Lewis, BS; Saely, CH; Fraunberger, P; Dobrev, D; Komiyama, M; Plattner, T; Agewall, S; Hasegawa, K (2023) Triglycerides Revisited: is Hypertriglyceridaemia a Necessary Therapeutic Target in Cardiovascular Disease? European Heart Journal - Cardiovascular Pharmacotherapy, 9 (6). pp. 570-582. ISSN 2055-6845 https://doi.org/10.1093/ehjcvp/pvad044
SGUL Authors: Kaski, Juan Carlos

[img] Microsoft Word (.docx) Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (89kB)
[img] Microsoft PowerPoint (Figure 1) Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (46kB)
[img] Microsoft PowerPoint (Figure 2) Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (104kB)
[img] Microsoft PowerPoint (Figure 3) Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (41kB)
[img] Microsoft PowerPoint (Figure 4) Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (44kB)
[img] Microsoft Word (.docx) (Table 1) Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (30kB)
[img] Microsoft Word (.docx) (Table 2) Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (36kB)
[img] Microsoft Word (.docx) (Table 3) Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (39kB)
[img] Microsoft Word (.docx) (Supplement 1) Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (17kB)
[img] Microsoft Word (.docx) (Supplement 2) Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (20kB)

Abstract

Despite the atherosclerotic cardiovascular disease (ASCVD) risk reduction achieved by low-density lipoprotein-cholesterol (LDL-C) lowering therapy, residual ASCVD risk still exists. Previous epidemiological studies have suggested high plasma triglycerides (TG) levels as a risk factor or risk marker for ASCVD independent of LDL-C levels. In this review, we highlighted the underlying pathophysiology of hypertriglyceridaemia, the mechanistic action of therapeutic agents, the interpretation of conflicting results on recent clinical trials, and the present options for primary and secondary prevention. The benefits of fibrates-induced reduction in TG and increase in high-density lipoprotein-cholesterol might outweigh the disadvantages of increasing LDL-C levels in primary prevention. In the secondary CVD prevention, using eicosapentaenoic acid without docosahexaenoic acid, in addition to statins, will be beneficial. This comprehensive review may prove useful for the development of novel approaches that target hypertriglyceridaemia in future.

Item Type: Article
Additional Information: This is a pre-copyedited, author-produced version of an article accepted for publication in European Heart Journal - Cardiovascular Pharmacotherapy following peer review. The version of record Heinz Drexel and others, Triglycerides Revisited: is Hypertriglyceridaemia a Necessary Therapeutic Target in Cardiovascular Disease?, European Heart Journal - Cardiovascular Pharmacotherapy, 2023;, pvad044 is available online at: https://doi.org/10.1093/ehjcvp/pvad044.
Keywords: 1102 Cardiorespiratory Medicine and Haematology, 1115 Pharmacology and Pharmaceutical Sciences
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: European Heart Journal - Cardiovascular Pharmacotherapy
ISSN: 2055-6845
Dates:
DateEvent
September 2023Published
16 June 2023Published Online
30 May 2023Accepted
Publisher License: Publisher's own licence
Projects:
Project IDFunderFunder ID
UNSPECIFIEDNational Hospital OrganizationUNSPECIFIED
URI: https://openaccess.sgul.ac.uk/id/eprint/115442
Publisher's version: https://doi.org/10.1093/ehjcvp/pvad044

Actions (login required)

Edit Item Edit Item